LYRA THERAPEUTICS INC LYRA
$0.25
+0.00%
at last close
Analyst Consensus
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2025-08-14 | HC Wainwright & Co.Matthew Caufield |
Reiterates | Neutral | $16 |
| 2025-06-10 | HC Wainwright & Co.Matthew Caufield |
Maintains | Neutral | $2 → $16 |
| 2025-03-14 | HC Wainwright & Co.Matthew Caufield |
Reiterates | Neutral | $2 |
| 2024-08-15 | Cantor FitzgeraldLouise Chen |
Reiterates | Overweight | — |
| 2024-08-15 | HC Wainwright & Co.Matthew Caufield |
Reiterates | Neutral | $2 |
| 2024-06-20 | Cantor FitzgeraldLouise Chen |
Reiterates | Overweight | — |
| 2024-05-07 | HC Wainwright & Co.Matthew Caufield |
Downgrades | Buy → Neutral | $2 |
| 2024-05-07 | JefferiesDennis Ding |
Downgrades | Buy → Hold | $10 → $1 |
| 2024-05-06 | BTIGJustin Zelin |
Downgrades | Buy → Neutral | — |
| 2024-05-01 | HC Wainwright & Co.Matthew Caufield |
Reiterates | Buy | $12 |
| 2024-03-25 | B of A SecuritiesJason Gerberry |
Maintains | Buy | $12 → $11 |
| 2024-03-22 | HC Wainwright & Co.Matthew Caufield |
Reiterates | Buy | $12 |
| 2023-10-06 | BTIGJustin Zelin |
Assumes | Buy | $15 |
| 2023-10-02 | HC Wainwright & Co.Matthew Caufield |
Reiterates | Buy | $12 |
| 2023-09-12 | B of A SecuritiesJason Gerberry |
Maintains | Buy | $13 → $15 |
| 2023-08-31 | HC Wainwright & Co.Matthew Caufield |
Initiates coverage on | Buy | $12 |
| 2023-02-07 | BTIGRobert Hazlett |
Maintains | Buy | $24 → $20 |
| 2022-05-24 | Cantor FitzgeraldLouise Chen |
Initiates coverage on | Overweight | $15 |
| 2020-05-26 | B of A SecuritiesJason Gerberry |
Initiates coverage on | Buy | $21 |
| 2020-05-26 | JefferiesChris Howerton |
Initiates coverage on | Buy | $24 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $0.25
- Market Cap
- —
- 52-Week Range
- $0.00 – $9.28
- Average Volume
- 15K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.